Pegylated Liposomal Doxorubicin Consolidation Therapy after Platinum/Paclitaxel-Based Chemotherapy for Suboptimally Debulked, Advanced-Stage Epithelial Ovarian Cancer Patients

Rocconi, Rodney P.; Straughn, J. Michael; Leath, Charles A.; Kilgore, Larry C.; Huh, Warner K.; Barnes, Mack N.; Partridge, Edward E.; Alvarez, Ronald D.

doi:10.1634/theoncologist.11-4-336

Cited by 13 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As to intravenous consolidation chemotherapy, most of the published studies did not observe any advantage in terms of survival. In particular, drugs used intravenously were topotecan [25], epidoxorubicin [26], pegylated liposomal doxorubicin [27,28] and platinum plus paclitaxel [29] given for an additional 3–4 cycles after completion of standard adjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Intraperitoneal Paclitaxel as Consolidation Treatment in Ovarian Cancer Patients: A Case Control Study

Panici¹,

Palaia²,

Graziano

et al. 2010

Oncology

View full text Add to dashboard Cite

Objective: It was the aim of this study to assess the role, feasibility and safety of consolidation intraperitoneal (IP) paclitaxel in patients affected by advanced ovarian cancer. Methods: Patients affected by advanced ovarian cancer with complete pathological response after standard treatment were enrolled in this study. The consolidation chemotherapy schedule consisted of 12–16 cycles of IP paclitaxel, 60 mg/mq weekly (group A). Chemotherapy was delivered with a direct puncture under ultrasonographic guidance at each cycle. Survival data of this group of patients were compared with those from a control group with analogous characteristics submitted to observation only (group B). Results: Seventy patients were included in the study, 28 in group A and 42 in group B. Treatment-related toxicity was mild. In 3/28 patients (11%), technical difficulties in accessing the peritoneum were observed. Median time to recurrence was 25 months (range 4–64) in group A and 17.5 months (range 2–60) in group B. Estimated 3-year disease-free survival was 56and 33% (p < 0.05) in group A and B, respectively; no significant difference in 3-year overall survival was observed (87 vs. 83%; p value not significant). Conclusion: Weekly IP consolidation chemotherapy with paclitaxel 60 mg/mq is well tolerated and, in this experience, a prolongation of progression-free survival was observed.

show abstract

Section: Discussionmentioning

confidence: 99%

Intraperitoneal Paclitaxel as Consolidation Treatment in Ovarian Cancer Patients: A Case Control Study

Panici¹,

Palaia²,

Graziano

et al. 2010

Oncology

View full text Add to dashboard Cite

show abstract

“…This in turn facilitates greater uptake of PLD by tumour cells resulting in 10-fold higher intracellular drug concentration in metastatic breast carcinoma tissue compared to normal tissue [36]. PLD is now considered the drug of choice for the treatment of relapsed ovarian cancer in terms of efficacy, less toxicity and cost effectiveness [37].…”

Section: P E G Y L a T E D L I P O S O M A L D O X O R U B I C I Nmentioning

confidence: 99%

Emerging trends of nanomedicine – an overview

Selvarajan

Dkhar

Chandrasekaran

2009

Fundamemntal Clinical Pharma

156

View full text Add to dashboard Cite

Nanotechnology is an emerging branch of science for designing tools and devices of size 1 to 100 nm with unique function at the cellular, atomic and molecular levels. The concept of using nanotechnology in medical research and clinical practice is known as nanomedicine. Nanoparticles possess some novel properties not seen with the macro molecules and they can be manipulated by attaching therapeutic components to help in diagnosis and treatment. They can also be used to probe cellular movements and molecular changes associated with pathological states. Nanodevices like carbon nanotubes to locate and deliver anticancer drugs at the specific tumour site are under research. Nanotechnology promises construction of artificial cells, enzymes and genes. This will help in the replacement therapy of many disorders which are due to deficiency of enzymes, mutation of genes or any repair in the synthesis of proteins. Currently nanodevices like respirocytes, microbivores and probes encapsulated by biologically localized embedding have a greater application in treatment of anaemia and infections. Thus in the present scenario, nanotechnology is spreading its wings to address the key problems in the field of medicine. Hence this review discusses in detail the applications of nanotechnology in medicine with more emphasis on drug delivery and therapy.

show abstract

“…It is one of the most commonly used and highly effective antineoplastic agents that is usually administered intravenously for the treatment of malignancies, including tumors of the breast, ovary, bladder, pancreas and thyroid (1). Nevertheless, the clinical use of this broad spectrum drug is also limited because of its poor stability and serious non-specific toxicity to normal tissues, which induces severe side effects such as acute dose limiting bone marrow toxicity and chronic cumulative cardiac toxicity (2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%

Antitumor activity of monomethoxy poly(ethylene glycol)-poly (ε-caprolactone) micelle-encapsulated doxorubicin against mouse melanoma

Qian¹

2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Doxorubicin (Dox) is one of the most commonly used and highly effective antineoplastic agents, but the clinical application of this broad spectrum drug is largely hampered by its poor stability and serious toxicity to normal tissues. Hence, it is essential to improve the therapeutic effect and decrease the systematic toxicity for the administration of doxorubicin. In our study, doxorubicin was incorporated into monomethoxy poly(ethylene glycol)-poly(Â-caprolactone) (MPEG-PCL) micelle by a self-assembly method. The cytotoxicity and cellular uptake efficiency of Dox-loaded MPEG-PCL (Dox/MPEG-PCL) micelle against B16-F10 murine melanoma cells was examined by the methylthiazoltetrazolium (MTT) test and flow cytometry. The antitumor activity of Dox/MPEG-PCL was evaluated in C57BL/6 mice injected subcutaneously with B16-F10 cells. Toxicity was evaluated in tumor-free mice. Meanwhile, tumor proliferation, intratumoal angiogenesis and apoptotic cells were evaluated by PCNA, CD31 staining and TUNEL assay, respectively. Encapsulation of doxorubicin in MPEG-PCL micelle improved the cytotoxicity of doxorubicin and enhanced its cellular uptake on B16-F10 cell in vitro. Administration of Dox/MPEG-PCL micelle resulted in significant inhibition (75% maximum inhibition relative to controls) in the growth of B16-F10 tumor xenografts and prolonged the survival of the treated mice (P<0.05). These anti-tumor responses were associated with marked increase of tumor apoptosis and notable reduction of cell proliferation and intratumoral microvessel density (P<0.05). The system toxicity also decreased in the Dox/MPEG-PCL group compared with free doxorubicin group. Our data indicate that the encapsulation of doxorubicin in MPEG-PCL micelle improved the anti-tumor activity in vivo without conspicuous systemic toxic effects.

show abstract

Pegylated Liposomal Doxorubicin Consolidation Therapy after Platinum/Paclitaxel-Based Chemotherapy for Suboptimally Debulked, Advanced-Stage Epithelial Ovarian Cancer Patients

Cited by 13 publications

References 15 publications

Intraperitoneal Paclitaxel as Consolidation Treatment in Ovarian Cancer Patients: A Case Control Study

Intraperitoneal Paclitaxel as Consolidation Treatment in Ovarian Cancer Patients: A Case Control Study

Emerging trends of nanomedicine – an overview

Antitumor activity of monomethoxy poly(ethylene glycol)-poly (ε-caprolactone) micelle-encapsulated doxorubicin against mouse melanoma

Contact Info

Product

Resources

About